Urigen And Kalium Inc. Sign Clinical Stage Licensing Agreement

Published: May 22, 2006

VANCOUVER, British Columbia, May 22 /PRNewswire/ -- Urigen Holdings Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications and Kalium Inc., a California-based boutique drug development company, today announced that Urigen has licensed Kalium's patents and technology for the use of suppositories to deliver drug therapies to treat diseases of the genitourinary tract.

Two Phase 2 clinical development programs targeting urology indications have been initiated. The first program, U301, is using the licensed technology platform to develop a prescription product for Acute Urethral Discomfort (AUD) while the focus of the second program, U302, is urethritis. Other medical indications are under review and will be advanced, as appropriate.

"We are pleased to have licensed this technology platform from Kalium as it enables Urigen to develop important and innovative treatments for the urology medical community. This license agreement demonstrates Urigen's commitment to be a leader in developing treatments for unmet and/or underserved urological indications," said William Garner, President and CEO Urigen.

Urigen is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen has five products in development for urology indications that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for which a Phase 2b study in on-going for the treatment of Chronic Pelvic Pain (CPP); U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting Acute Urethral Discomfort; and U302, targeting urethritis.

CONTACT: Urigen Holdings Inc. Martin Shmagin, CFO 415-971-1080 marty@urigen.comwww.urigen.com

This news release contains forward-looking statements about the potential commercialization of the technology platforms Urigen Holdings Inc. has in-licensed that reflects management's current beliefs. However, as with any pharmaceutical under development, there are significant risks in development, regulatory approval and commercialization of new compounds. There are no guarantees that future clinical studies will confirm the preliminary results discussed in this news release or that a product or products utilizing these technology platforms will receive regulatory approval for any indication. Further, even if the company were to receive regulatory approval for a product, there can be no assurance that such a product would prove to be commercially successful.

Urigen Holdings Inc.

CONTACT: Martin Shmagin, CFO of Urigen Holdings Inc., +1-415-971-1080, ormarty@urigen.com

Back to news